HANSOH PHARMA AND QYUNS ANNOUNCE LICENSING AGREEMENT AND STRATEGIC COLLABORATION FOR QX004N
On April 25, 2024, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), China's leading innovation-driven pharmaceutical company, and Qyuns Therapeutics Co., Ltd. (Qyuns, 02509.HK), a biopharmaceutical company focusing on antibody drugs for autoimmune and allergic diseases, announced that the two parties have entered into a license agreement on Monoclonal Antibody QX004N (“QX004N”) independently developed by Qyuns on April 24.
Pursuant to the Licensing Agreement, Hansoh Pharma has obtained an exclusive license from Qyuns to develop and commercialize QX004N within China (including Hong Kong, Macau and Taiwan).Hansoh Pharma will be responsible for the research and development (“R&D”), manufacturing and commercialization of QX004N in all developable dosage forms and indications in China, and will pay an upfront payment of RMB75 million and potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB1,032 million, plus tiered royalties on future product sales.
QX004N is an innovative drug candidate indicated for psoriasis and Crohn’s disease. As of the date of this announcement, QX004N has been initiated in various clinical studies, with the highest stage of development in China being a Phase II clinical trial.
“Hansoh Pharma is actively seeking potential blockbuster products in the autoimmune field,” said Ms Eliza Sun, Executive Director of the Board at Hansoh. “Through this collaboration with Qyuns, we will further expand our pipeline portfolio for the treatment of autoimmune diseases and provide better treatment options for patients with chronic autoimmune diseases.”
“We are thrilled to enter into the strategic partnership with Hansoh,” said Mr. Jiwan Qiu, Founder, Chairman and CEO of Qyuns. “As a leading pharmaceutical company in China, Hansoh's rich development experience and seasoned sales network will strongly support the development of QX004N. We believe that with the joint efforts of both sides, QX004N will benefit patients suffering from psoriasis and other related diseases in the near future.”
About Hansoh Pharma
Hansoh Pharma is a leading pharmaceutical company in Greater China driven by innovation. It is committed to the treatment of major diseases in the areas of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases, and is dedicated to improving human health through continuous innovation. Hansoh Pharma has been ranked among the top 100 global pharmaceutical companies and the top 3 best industrial enterprises in China in terms of pharmaceutical R&D pipeline for several years, and is a national key high-tech enterprise and a national technology innovation demonstration enterprise. Hansoh Pharma was listed on the Stock Exchange of Hong Kong in June, 2019 (stock code: 03692.HK). For more information, please visit www.hspharm.com.
About Qyuns
Founded in 2015, Qyuns Therapeutics (02509.HK) is a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases with a self-developed drug pipeline and established commercial-scale in-house manufacturing capability. Adhering to the vision of "innovation for the great majority", Qyuns strives to improve drug accessibility and affordability in focused disease areas. Based on its independent innovation capabilities, Qyuns has built a comprehensive pipeline, including 1 product with BLA acceptance, 1 product at phase III clinical stage, 4 products at phase II or phase I, with indications covering the four major disease areas of skin, respiratory, digestive, and rheumatism. Qyuns is one of those who received the most IND approvals regarding autoimmune and allergic diseases in China. For further information, please refer to https://www.qyuns.net.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
